Jagsonpal Pharmaceuticals Ltd News
USFDA pulls up Jagsonpal Pharma for manufacturing lapses at API plant
The US health regulator has pulled up Jagsonpal Pharmaceuticals for significant manufacturing lapses at its Rajasthan-based active pharmaceutical ingredients (APIs) plant. In a warning letter issued to the company's Managing Director Manish Gupta, the US Food and Drug Administration (USFDA) noted that the correspondence summarizes significant deviations from Current Good Manufacturing Practice for APIs. The US health regulator stated that it inspected the company's Bhiwadi- based plant in Rajasthan on March 20, March 27, and April 3, 2024. "This warning letter summarises significant deviations from Current Good Manufacturing Practice (CGMP) for APIs. Because the methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API is adulterated," the USFDA stated in the warning letter. A warning letter issued by the USFDA usually identifies the violation, such as poor manufacturing practices, problems with claims for what a product ca
 "USFDA pulls up Jagsonpal Pharma for manufacturing lapses at API plant")
Jagsonpal Pharma shares jump 10% after stellar Q3 results; know more
Gurugram-based Jagsonpal Pharmaceuticals share price gained 10.3 per cent at Rs 252 a piece on the BSE in Thursday's intraday trade
 "Jagsonpal Pharma shares jump 10% after stellar Q3 results; know more")
